News

Home / News
Milla Pharmaceuticals announces Third ANDA approval and the 4th U.S. approval for the Alter Pharma Group

Milla Pharmaceuticals announces Third ANDA approval and the 4th U.S. approval for the Alter Pharma Group

Milla Pharmaceuticals Inc., announces U.S. Food and Drug Administration (FDA) has granted approval to the Company’s Abbreviated New Drug Application (ANDA) for a generic version of Mestinon® (Pyridostigmine Bromide Syrup) 60 mg/5mL. Pyridostigmine Bromide Syrup is indicated for symptomatic treatment of myasthenia gravis. Myasthenia gravis is a neuromuscular disorder primarily characterized by muscle weakness and rapid muscle fatigue. This achievement marks Milla Pharmaceutical’s third ANDA approval within a year and the 4th ANDA approval of an Alter Pharma product, thereby clearing the path for a 4th launch of an Alter Pharma product in the U.S. market. “Once might be luck,...

Read More
Alter Pharma acquires EcoPharmaSupply

Alter Pharma acquires EcoPharmaSupply

The Alter Pharma Group is proud to announce having acquired EcoPharmaSupply (EPS). EPS is a Belgian pharmaceutical services and products company, distributor and partner of choice for several pharmaceutical brands on the Benelux market including prescription drugs, medical devices, OTC pharmaceuticals and consumer health products. The investment will allow Alter Pharma to enhance its services and product offering further leveraging its regulatory compliance and market know-how while leaning on its extensive procurement and logistics network. Through this acquisition, which was closed on 4 April 2022, Alter Pharma further expands its toolkit for supporting both retail and hospital pharmacists in their quest to deliver high quality service and products to their patients. Please...

Read More
Milla Pharmaceuticals Announces Approval of a Generic Version of Magnesium Sulfate in Water for Injection, in Non-PVC, Single-Patient Use Containers.

Milla Pharmaceuticals Announces Approval of a Generic Version of Magnesium Sulfate in Water for Injection, in Non-PVC, Single-Patient Use Containers.

Milla Pharmaceuticals, a subsidiary of the Alter Pharma Group, announced that it has received abbreviated new drug application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for its generic version of Magnesium Sulfate in Water for Injection, 2 g/50 mL (40 mg/mL), 4 g/100 mL (40 mg/mL), and 4 g/50 mL (80 mg/mL), in Non-PVC, Single-Patient Use Containers (Magnesium Sulfate Injection). Magnesium Sulfate Injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. When used judiciously, it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous...

Read More